A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia

Registry ID

EUCTR2010-023742-79

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

AEGERION PHARMACEUTICALS

Start date

2011-03-25

Completion date

2015-02-10

Last update

2026-08-16

Conditions

• Homozygous Familial Hypercholesterolemia

Summary

The primary objective of the study is to evaluate the efficacy of lomitapide, as defined by percent change in LDL-C at the maximum tolerated dose at Week 48 compared to baseline, in combination with other lipid lowering therapy in patients with homozygous familial hypercholesterolemia (FH) who completed study UP1002 or 733-005.

Locations

• , , Italy

Related clinical trials

• The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
• HoFH, the International Clinical Collaborators Registry
• NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia

View on source registry